Preliminary results of the study conducted by drug maker Eli Lilly have not been peer-reviewed or published<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Jan. 22, 2021 (HealthDay News) — An antibody drug that has emergency use authorization from the U.S. Food and Drug Administration for use in early-stage COVID-19 patients with symptoms prevented COVID-19 infections in nursing residents and staff who were exposed to the virus, a new study shows.<\/p>\n
It was conducted to find out if bamlanivimab could protect nursing home residents and staff against infections with the new coronavirus, The New York Times<\/em> reported. In the study, mobile labs and medical workers were sent to nursing homes immediately after a single infection was detected, and temporary infusion centers were set up to administer the drug.<\/p>\n The study included 299 residents and 666 staff. Some received the drug and others were given a placebo. Compared with those who received placebo, rates of symptomatic infections were 80 percent lower among residents and 60 percent lower among staff who received the drug, The Times<\/em> reported.<\/p>\n The preliminary results of the study conducted by drug maker Eli Lilly have not been peer-reviewed or published. The company said it expects to present the results at a medical meeting and to publish them in a peer-reviewed journal but provided no timeline, The Times<\/em> reported.<\/p>\n